Emmes, a global, full-service Clinical Research Organization (CRO) has acquired Casimir, a U.S.-based CRO. Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit.

Emmes Chief Executive Officer Dr. Christine Dingivan said, “This is the fourth acquisition for Emmes in just over a year, as we continue to add new biopharma clients and deepen our innovative research capabilities.  The combination of Casimir and Emmes will further differentiate our global rare disease center of excellence, Orphan Reach™.  We plan to continue and accelerate the groundbreaking work of Casimir in neurodegenerative and neuromuscular conditions with remote data capture and patient outcome standardization.”

Founded in 2016, Casimir is supporting 39 projects with 25 different clients. It is especially well known for its efforts in Duchenne Muscular Dystrophy (DMD) and the application of its proprietary Duchenne Video Assessment (DVA) tool that measures clinical outcomes via remote data capture.  The DVA is actively being explored in a variety of other rare disease indications, as well as in other neurogenerative/neuromuscular diseases. 

Rare disease research is a strategic priority for Emmes.  The company established Orphan Reach: Emmes’ Rare Disease Center to combine its expertise in biostatistics, data management and clinical research with Orphan Reach’s rare disease patient-centric focus.  Now, with Casimir’s proprietary clinical outcomes technology, Emmes establishes itself as the industry-leading CRO in rare and orphan disease clinical research and drug development.

Casimir’s CEO and Co-Founder Christine McSherry said, “Emmes’ long history and passion to improve public health were instrumental in our decision to join this outstanding company.  The size and reach of Emmes will give us an even greater ability to expand our current platform and outcomes development expertise to other neurodegenerative diseases and therapeutic areas.”